Historical Valuation
Maia Biotechnology Inc (MAIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.51. The fair price of Maia Biotechnology Inc (MAIA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.63
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Maia Biotechnology Inc (MAIA) has a current Price-to-Book (P/B) ratio of 1323.41. Compared to its 3-year average P/B ratio of 109.78 , the current P/B ratio is approximately 1105.52% higher. Relative to its 5-year average P/B ratio of 95.66, the current P/B ratio is about 1283.41% higher. Maia Biotechnology Inc (MAIA) has a Forward Free Cash Flow (FCF) yield of approximately -25.70%. Compared to its 3-year average FCF yield of -34.76%, the current FCF yield is approximately -26.08% lower. Relative to its 5-year average FCF yield of -33.35% , the current FCF yield is about -22.96% lower.
P/B
Median3y
109.78
Median5y
95.66
FCF Yield
Median3y
-34.76
Median5y
-33.35
Competitors Valuation Multiple
AI Analysis for MAIA
The average P/S ratio for MAIA competitors is 1.95, providing a benchmark for relative valuation. Maia Biotechnology Inc Corp (MAIA.A) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MAIA
1Y
3Y
5Y
Market capitalization of MAIA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MAIA in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MAIA currently overvalued or undervalued?
Maia Biotechnology Inc (MAIA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.51. The fair price of Maia Biotechnology Inc (MAIA) is between NaN to NaN according to relative valuation methord.
What is Maia Biotechnology Inc (MAIA) fair value?
MAIA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Maia Biotechnology Inc (MAIA) is between NaN to NaN according to relative valuation methord.
How does MAIA's valuation metrics compare to the industry average?
The average P/S ratio for MAIA's competitors is 1.95, providing a benchmark for relative valuation. Maia Biotechnology Inc Corp (MAIA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Maia Biotechnology Inc (MAIA) as of Jan 10 2026?
As of Jan 10 2026, Maia Biotechnology Inc (MAIA) has a P/B ratio of 1323.41. This indicates that the market values MAIA at 1323.41 times its book value.
What is the current FCF Yield for Maia Biotechnology Inc (MAIA) as of Jan 10 2026?
As of Jan 10 2026, Maia Biotechnology Inc (MAIA) has a FCF Yield of -25.70%. This means that for every dollar of Maia Biotechnology Inc’s market capitalization, the company generates -25.70 cents in free cash flow.
What is the current Forward P/E ratio for Maia Biotechnology Inc (MAIA) as of Jan 10 2026?
As of Jan 10 2026, Maia Biotechnology Inc (MAIA) has a Forward P/E ratio of -2.32. This means the market is willing to pay $-2.32 for every dollar of Maia Biotechnology Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Maia Biotechnology Inc (MAIA) as of Jan 10 2026?
As of Jan 10 2026, Maia Biotechnology Inc (MAIA) has a Forward P/S ratio of 0.00. This means the market is valuing MAIA at $0.00 for every dollar of expected revenue over the next 12 months.